- Home
- PTGX vs AKRO Comparison
PTGX vs AKRO Comparison
Compare PTGX & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- AKRO
- Stock Information
- Founded
- PTGX 2006
- AKRO 2017
- Country
- PTGX United States
- AKRO United States
- Employees
- PTGX N/A
- AKRO N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PTGX Health Care
- AKRO Health Care
- Exchange
- PTGX Nasdaq
- AKRO Nasdaq
- Market Cap
- PTGX 2.7B
- AKRO 2.2B
- IPO Year
- PTGX 2016
- AKRO 2019
- Fundamental
- Price
- PTGX $41.49
- AKRO $29.34
- Analyst Decision
- PTGX Strong Buy
- AKRO Strong Buy
- Analyst Count
- PTGX 8
- AKRO 8
- Target Price
- PTGX $54.63
- AKRO $46.83
- AVG Volume (30 Days)
- PTGX 767.3K
- AKRO 610.0K
- Earning Date
- PTGX 11-07-2024
- AKRO 11-08-2024
- Dividend Yield
- PTGX N/A
- AKRO N/A
- EPS Growth
- PTGX N/A
- AKRO N/A
- EPS
- PTGX 2.68
- AKRO N/A
- Revenue
- PTGX $323,795,000.00
- AKRO N/A
- Revenue This Year
- PTGX $441.08
- AKRO N/A
- Revenue Next Year
- PTGX N/A
- AKRO N/A
- P/E Ratio
- PTGX $15.46
- AKRO N/A
- Revenue Growth
- PTGX 125.73
- AKRO N/A
- 52 Week Low
- PTGX $21.43
- AKRO $15.32
- 52 Week High
- PTGX $48.89
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- PTGX 48.12
- AKRO 45.72
- Support Level
- PTGX $38.61
- AKRO $27.35
- Resistance Level
- PTGX $41.18
- AKRO $31.41
- Average True Range (ATR)
- PTGX 1.93
- AKRO 1.56
- MACD
- PTGX -0.01
- AKRO -0.21
- Stochastic Oscillator
- PTGX 59.02
- AKRO 42.16
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.